Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04888988 | Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy(CIPN) | active not recruiting | N/A | 133 | University of Rochester NCORP Research BaseOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04890834 | Dyadic Yoga Intervention for the Improvement of Healthcare Utilization and Quality of Life in Patients With Head and Neck Cancer Undergoing Chemoradiation and Their Caregivers | active not recruiting | N/A | 415 | M.D. Anderson Cancer CenterOTHER |
| 1 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT04906395 | Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer(OVELIA) | active not recruiting | Phase 3 | 250 | Tolmar Inc.INDUSTRY | 7 | Sep 29, 2026 | clinicaltrials |
| NCT04912739 | Targeted Health Dialogues in Primary Care | recruiting | — | 18,000 | Region SkaneOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04958239 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | active not recruiting | Phase 1 | 151 | Boehringer IngelheimINDUSTRY | 15 | Sep 29, 2026 | clinicaltrials |
| NCT04981509 | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | recruiting | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05038735 | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.(EPIK-B5) | active not recruiting | Phase 3 | 210 | Novartis PharmaceuticalsINDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT05051722 | Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer(ECHO) | recruiting | — | 3,110 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05079282 | Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | active not recruiting | Phase 1 | 217 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05081193 | Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer | active not recruiting | Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05128825 | A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer(DENALI) | recruiting | Phase 2 | 310 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 8 | Sep 29, 2026 | clinicaltrials |
| NCT05132582 | A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer(HER2CLIMB-05) | active not recruiting | Phase 3 | 654 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 23 | Sep 29, 2026 | clinicaltrials |
| NCT05148156 | Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer. | recruiting | N/A | 20 | Northwell HealthOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05212246 | Basal Cell Carcinoma Chemoprevention Trial(B3C) | not yet recruiting | Phase 3 | 1,630 | VA Office of Research and DevelopmentFED | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | recruiting | Phase 3 | 360 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT05287451 | Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study | recruiting | N/A | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05296798 | A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | active not recruiting | Phase 3 | 922 | Hoffmann-La RocheINDUSTRY | 29 | Sep 29, 2026 | clinicaltrials |
| NCT05304208 | dENdritic Cell Therapy Combined With SURgEry in Mesothelioma(ENSURE) | recruiting | Phase 1 | 16 | Erasmus Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05322590 | BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma(ASIST) | active not recruiting | Phase 1 / Phase 2 | 195 | Bexion Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05354557 | Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) | active not recruiting | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05390827 | Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol | recruiting | — | 3,692 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | recruiting | Phase 2 | 2,900 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT05604105 | Oral Cancer Awareness in Egypt | not yet recruiting | — | 1,844 | Ayat Gamal-AbdelNaserOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT05611034 | In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung | recruiting | Phase 1 | 10 | University Health Network, TorontoOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05685004 | Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | active not recruiting | Phase 2 / Phase 3 | 120 | TVAX BiomedicalINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05731271 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 111 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05741242 | A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors | enrolling by invitation | Phase 1 / Phase 2 | 136 | Jaime Leandro Foundation for Therapeutic Cancer VaccinesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05768711 | Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)(AVENHIR) | active not recruiting | Phase 2 | 44 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05803382 | Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05845671 | Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations | active not recruiting | Phase 1 / Phase 2 | 12 | University of Colorado, DenverOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05856773 | Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy(COMPRO) | recruiting | Phase 3 | 276 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05864534 | Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 25 | Northwestern UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05871021 | Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma(PRIDE) | active not recruiting | Phase 2 | 107 | University Hospital TuebingenOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05874921 | uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto(uTRACT) | recruiting | — | 450 | UroGen Pharma Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05875168 | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 590 | Daiichi SankyoINDUSTRY | 8 | Sep 29, 2026 | clinicaltrials |
| NCT05877599 | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | recruiting | Phase 1 | 45 | AstraZenecaINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers(ARC-25) | active not recruiting | Phase 1 | 40 | Arcus Biosciences, Inc.INDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT05902169 | Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM(SONOBIRD) | recruiting | Phase 3 | 560 | CarTheraINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT05927142 | Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy(DURIPANC) | active not recruiting | Phase 1 / Phase 2 | 43 | Joachim Aerts, MD PhDOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05952024 | Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL(ACRUE) | recruiting | Phase 2 | 80 | AstraZenecaINDUSTRY | 5 | Sep 29, 2026 | clinicaltrials |
| NCT05987241 | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | recruiting | Phase 2 / Phase 3 | 992 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT05987956 | Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Medicine Invention Design, IncINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06046794 | Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients(GemSign-01) | recruiting | N/A | 100 | Institut Paoli-CalmettesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | recruiting | Phase 3 | 3,680 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT06093425 | Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma | not yet recruiting | Phase 3 | 820 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | recruiting | Phase 2 / Phase 3 | 224 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06303193 | Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | recruiting | Phase 1 / Phase 2 | 160 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06309225 | Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly((DACHOC-E)) | recruiting | N/A | 20 | Omar MahmoudOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | recruiting | Phase 3 | 600 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
Data updated 11 hours agoSource updated Sep 29, 2026source: clinicaltrials